Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2026)

Aytu Biopharma has reported Non-Current Debt over the past 6 years, most recently at $10.0 million for Q4 2025.

  • Quarterly Non-Current Debt changed 0.15% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, changed 0.15% year-over-year, with the annual reading at $10.9 million for FY2025, 0.17% changed from the prior year.
  • Non-Current Debt was $10.0 million for Q4 2025 at Aytu Biopharma, down from $10.4 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $15.0 million in Q4 2023 and troughed at $129000.0 in Q4 2021.
  • The 5-year median for Non-Current Debt is $10.9 million (2024), against an average of $10.3 million.
  • Year-over-year, Non-Current Debt plummeted 98.7% in 2021 and then soared 11165.89% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $129000.0 in 2021, then soared by 11165.89% to $14.5 million in 2022, then grew by 3.06% to $15.0 million in 2023, then crashed by 33.35% to $10.0 million in 2024, then grew by 0.15% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non-Current Debt are $10.0 million (Q4 2025), $10.4 million (Q3 2025), and $10.9 million (Q2 2025).